Table 1.
In vitro efficacy of fidaxomicin and ribavirin against 2 different ZIKV strains in 4 different cell lines
| ZIKV strain | Cell line | Fidaxomicin | Ribavirin | ||||
|---|---|---|---|---|---|---|---|
| EC50 (μM)a | EC90 (μM)b | CC50 (μM)c | EC50 (μM)a | EC90 (μM)b | CC50 (μM)c | ||
| ZG-01 | Vero | 11.7 ± 2.1 | 48.2 ± 5.3 | 126.0 ± 10.3 | > 100 | > 100 | 485.5 ± 20.1 |
| SNB19 | 6.0 ± 1.0 | 8.9 ± 0.6 | 113.7 ± 9.9 | > 100 | > 100 | 478.2 ± 17.2 | |
| Huh7 | 7.7 ± 1.7 | 17.8 ± 3.5 | 76.4 ± 5.8 | 12.7 ± 2.3 | 54.3 ± 3.5 | 491.8 ± 19.4 | |
| A549 | 12.2 ± 3.6 | 39.5 ± 4.8 | 135.8 ± 12.1 | 33.2 ± 3.4 | 71.6 ± 6.2 | 170.1 ± 25.9 | |
| MR766 | Vero | 12.4 ± 3.0 | 45.2 ± 6.2 | 126.0 ± 10.3 | > 100 | > 100 | 485.5 ± 20.1 |
| SNB19 | 6.8 ± 1.2 | 9.5 ± 1.5 | 113.7 ± 9.9 | > 100 | > 100 | 478.2 ± 17.2 | |
| Huh7 | 7.3 ± 2.5 | 16.2 ± 3.9 | 76.4 ± 5.8 | 15.6 ± 2.1 | 58.3 ± 3.2 | 491.8 ± 19.4 | |
| A549 | 13.0 ± 4.4 | 42.2 ± 4.6 | 135.8 ± 12.1 | 35.2 ± 5.2 | 74.6 ± 8.5 | 170.1 ± 25.9 | |
aThe 50% effective concentration, or the concentration necessary to reduce viral yield by 50%, was determined using a plaque assay
bThe 90% effective concentration, or the concentration necessary to reduce viral yield by 90%, was determined using a plaque assay
cConcentration required to inhibit the cell growth by 50% in the absence of virus